Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best strong buy stocks to invest in according to Wall Street. On September 25, RBC Capital initiated coverage of Apogee Therapeutics Inc. (NASDAQ:APGE) with an Outperform rating and a $60 price target. Is Exact Sciences Corporation (NASDAQ:EXAS) the Gene Therapy Stock with the Greatest Potential? The firm expressed optimistic sentiments regarding the company’s potential to deliver clinically differentiated biologics, telling investors in a research not ...

LONDON, UNITED KINGDOM / ACCESS Newswire / September 30, 2025 / Genflow (LSE:GENF)(OTCQB:GENFF) is pleased to announce its half year results for the six-month period ended 30 June 2025. Chairman's Statement It is my pleasure to update shareholders of Genflow Biosciences Plc ("Genflow" or the "Company") on our performance during the first six months of 2025. ...

Core Insights - Several healthcare and biotech stocks experienced significant price movements on September 29, driven by clinical trial updates, regulatory progress, and strategic announcements Company Performance Highlights - Phio Pharmaceuticals Corp. (PHIO) saw an 8.9% increase in after-hours trading, rising from $2.36 to $2.57, following a 5.83% gain during the regular session, attributed to a positive safety committee recommendation for its PH-762 skin cancer trial [1][2] - Barinthus Biotherapeutics plc (BRNS) rose 8.11% in after-hours trading to $1.60 after closing at $1.48, with a notable 21.3% gain, driven by renewed interest in its immunotherapeutic pipeline [2][3] - Neogen Corp. (NEOG) jumped 5.59% in after-hours trading to $5.90, reversing a 1.41% decline earlier in the day, following announcements of its upcoming earnings release and a renewed sponsorship agreement [3][4] - OKYO Pharma Ltd. (OKYO) increased by 9% in after-hours trading to $2.18 after a decline of 8.26% during the regular session, due to renewed focus on its clinical-stage program for urcosimod [5] - Aurinia Pharmaceuticals Inc. (AUPH) rose 8.05% in after-hours trading to $11.95, despite a 15.83% drop earlier, reflecting heightened activity around its lupus nephritis treatment, LUPKYNIS, and a collaboration with Otsuka Pharmaceutical [6] - RAPT Therapeutics, Inc. (RAPT) climbed 4.43% in after-hours trading to $27.80, following the FDA's clearance of its IND application for RPT904, allowing it to proceed with a Phase 2b trial targeting food allergies [7][8]

Company Overview - SSI International transitioned from financial struggles in 2023 to a successful Nasdaq listing in 2025, achieving a market cap exceeding $1 billion [1] - The company, founded by Sudhir Srivastava, has established itself in the medical technology sector, particularly in robotic surgical systems, competing with industry leader Intuitive Surgical [2] Business Development - SSI International has made significant progress since 2015, now shipping surgical systems weekly, with at least 115 units deployed across major hospitals in India and several other countries [3] - The company reported trailing 12-month revenue of $27.6 million as of June and has engaged an investment bank for public fundraising [4] Market Strategy - SSI went public through a merger with Avra Medical Robotics, allowing it to bypass traditional IPO processes [4] - The company aims to maintain capital efficiency in its operations, as emphasized by co-founder Shiladitya Sengupta [6] Industry Context - Vyome Therapeutics, another Indian biotech firm, successfully listed on Nasdaq via a reverse merger, highlighting a trend among Indian companies seeking alternative routes to public markets [5]

Summary of Key Points from the Capex Tracker Industry Overview - The Capex Tracker indicates a trend of capital expenditure (Capex) cuts across various industries, with notable exceptions in Technology and Utilities [3][4]. Core Observations - General Industrial Capex is projected to have a compound annual growth rate (CAGR) of 5.5% for the period 2024-2028, which is a slight decrease of 0.4 percentage points compared to the previous update in July [3][4]. - Positive growth in Capex is observed in the following sectors: - **Datacenters**: 26.5% CAGR, an increase of 3.5 percentage points from July [4]. - **Pulp & Paper**: Improvement noted, but specific growth figures not provided [3]. - **Conventional Power Generation**: Positive outlook with companies like Wartsila and Accelleron showing growth [3]. - **Mining**: Companies such as Epiroc and FLSmidth are expected to benefit [3]. - Conversely, significant declines are noted in: - **Vehicles/Autos**: Negative growth, with a decrease of 1.8 percentage points to 2.0% CAGR [4]. - **Pharma and Biotech**: Both sectors are experiencing negative trends, with Biotech showing a decline of 8.6% [4]. Detailed Capex Growth by Sector - **Datacenters**: - 2025 Capex growth projected at 51.7%, a significant increase of 15.2 percentage points [4]. - **Renewables and T&D**: - 2025 Capex growth at 17.5%, down by 8.0 percentage points [4]. - **Semiconductors**: - 2025 Capex growth at 15.7%, a decrease of 1.2 percentage points [4]. - **Healthcare**: - 2025 Capex growth projected at 0.0%, indicating stagnation [4]. - **Consumer Sector**: - 2025 Capex growth at 0.7%, reflecting a decline of 1.1 percentage points [4]. Additional Insights - The Capex Tracker highlights a robust growth trajectory in Datacenters, Renewables, and Mining, while traditional sectors like Vehicles and Pharma are facing headwinds [4]. - The report emphasizes the importance of monitoring these trends for potential investment opportunities and risks in the respective sectors [3][4]. Conclusion - The Capex Tracker serves as a critical tool for understanding industry trends and making informed investment decisions, particularly in identifying sectors poised for growth versus those facing challenges [3][4].

Core Viewpoint - Anaptys plans to separate its biopharma operations from its royalty assets to maximize value by creating two distinct companies with different business objectives and opportunities [2]. Company Overview - Anaptys has a 20-year history of generating best-in-class antibodies, with notable successes including Jemperli and imsidolimab, which have positively impacted patient lives and generated financial collaborations [3]. Financial Performance - Jemperli has shown impressive commercial uptake over the past 12 months, with anticipated future growth contributing to a significant tiered royalty stack from GSK that benefits Anaptys [4].

Core Viewpoint - MoonLake Immunotherapeutics is under investigation for potential violations of federal securities laws following disappointing results from its Phase 3 VELA trials for sonelokimab, leading to a significant drop in stock price [1][3]. Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on therapies for inflammatory skin and joint diseases [2]. Trial Results - On September 29, 2025, MoonLake reported week 16 results from the VELA Phase 3 trials, which were highly anticipated but yielded disappointing outcomes, raising concerns about the drug's regulatory approval and commercial viability [3]. Stock Market Impact - Following the announcement of the trial results, MoonLake's stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 28, 2025, to $6.24 on September 29, 2025 [3].

Core Insights - Abivax announced the acceptance of an additional late-breaking abstract for its lead drug candidate, obefazimod, to be presented at the 2025 United European Gastroenterology Congress, highlighting its significance in treating moderately to severely active ulcerative colitis [1][2] Group 1: Presentation Details - The late-breaking abstract titled "EFFICACY AND SAFETY OF OBEFAZIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS" will be presented on October 5, 2025, at 5 PM CEST [1] - The presentation will include results from two Phase 3 randomized, double-blind, placebo-controlled, 8-week induction trials (ABTECT-1 & 2) [1][3] Group 2: Clinical Significance - The results from the ABTECT Phase 3 induction trials demonstrate statistically significant and clinically meaningful activity, along with an impressive safety and tolerability profile for obefazimod [2] - These findings are seen as crucial steps towards providing a novel, first-in-class oral treatment option for patients with ulcerative colitis [2] Group 3: Company Overview - Abivax is a clinical-stage biotechnology company focused on developing therapies that stabilize the immune response in patients with chronic inflammatory diseases [5] - The company is based in France and the United States, with obefazimod currently in Phase 3 clinical trials for ulcerative colitis [5]

Core Insights - Cogent Biosciences, Inc. announced the approval of inducement equity awards for 10 new employees as part of its 2020 Inducement Plan, in compliance with Nasdaq corporate governance rules [1][2] Group 1: Inducement Equity Awards - The Compensation Committee approved nonqualified options to purchase a total of 299,200 shares of Cogent common stock for the new employees [2] - Each option has a 10-year term with an exercise price equal to the closing price on the grant date, and a four-year vesting schedule [2] Group 2: Company Overview - Cogent Biosciences focuses on developing precision therapies for genetically defined diseases, with its most advanced clinical program being bezuclastinib, a selective tyrosine kinase inhibitor [3] - Bezuclastinib targets the KIT D816V mutation, which is linked to systemic mastocytosis and advanced gastrointestinal stromal tumors (GIST) [3] - The company is also conducting a Phase 1 study of a novel FGFR2/3 inhibitor and developing therapies targeting mutations in ErbB2, PI3Kα, and KRAS [3]

Core Points - bioAffinity Technologies has announced the pricing of a public offering amounting to $4.8 million [1] Company Summary - The public offering is part of bioAffinity Technologies' strategy to raise capital for its operations and growth initiatives [1]